Please login first
Kristin Clothier   Dr.  Institute, Department or Faculty Head 
Timeline See timeline
Kristin Clothier published an article in February 2018.
Publication Record
Distribution of Articles published per year 

Total number of journals
published in
Article 0 Reads 1 Citation Frequency, serotype distribution, and antimicrobial susceptibility patterns of Salmonella in small poultry flocks in Cal... Kristin A. Clothier, Peony Kim, Aslı Mete, Ashley E. Hill Published: 06 February 2018
Journal of Veterinary Diagnostic Investigation, doi: 10.1177/1040638718755418
DOI See at publisher website
Article 0 Reads 0 Citations Characterization of Pajaroellobacter abortibovis , the etiologic agent of epizootic bovine abortion Roxann S. Brooks, Myra T. Blanchard, Kristin A. Clothier, Sc... Published: 01 August 2016
Veterinary Microbiology, doi: 10.1016/j.vetmic.2016.07.001
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Highlights•The agent of epizootic bovine abortion has been named Pajaroellobacter abortibovis.•Gram stain and electron microscopy confirm P. abortibovis to be a gram negative rod.•Flow cytometric analysis establishes the intracellular presence of P. abortibovis in leukocytes.•Pajaroellobacter abortibovis partial gene sequences were established for 23 S rRNA, fusA and pyrG.•Phylogenic analysis places P. abortibovis in a genus unique from Sorangium. AbstractEpizootic bovine abortion (EBA), first identified in the 1950s, is a major contributor of economic loss to western U.S. beef producers. The causative agent proved elusive for over fifty years until a novel Deltaproteobacteria was identified as the etiologic agent in 2005. The microbe, which has yet to be successfully cultured in vitro, has proven difficult to purify from necropsy tissues. Thus, phylogenetic characterization has been limited to analysis of the 16 S ribosomal RNA (rRNA) gene (AF503916), which placed this bacterium in the order Myxococcales, suborder Sorangiineae, family Polyangiaceae and most closely related to Sorangium cellulosum. The focus of the current study was to further expand the morphologic characterization and taxonomic placement of this bacteria, named here as Pajaroellobacter abortibovis. Modified Gram staining, combined with transmission electron microscopy, provide strong evidence that the bacterium is gram negative. Flow cytometric analysis identified the presence of P. abortibovis in murine leukocytes. While attempts to sequence ten universally conserved protein-coding genes using previously published degenerative primers failed, redesigned primers based solely upon Deltaproteobacteria facilitated the partial sequencing of two genes; fusA (JQ173112) and pyrG (JQ173111). Primers designed in a similar fashion generated a partial sequence of the 23 S rRNA gene (JQ173113) These sequences, combined with a revised 16 S rRNA phylogenic analysis, support the placement of this bacteria as a unique genus separate from Sorangium.
Article 0 Reads 5 Citations Evaluation of bovine abortion cases and tissue suitability for identification of infectious agents in California diagnos... K. Clothier, M. Anderson, Press Enter Key For Correspondence... Published: 01 March 2016
Theriogenology, doi: 10.1016/j.theriogenology.2015.11.001
DOI See at publisher website PubMed View at PubMed
Conference papers
CONFERENCE-ARTICLE 36 Reads 0 Citations High Efficiency Drug Repurposing for New Antifungal Agents Jong H. Kim, Kathleen L. Chan, Luisa W. Cheng, Lisa A. Tell,... Published: 03 November 2018
doi: 10.3390/ecmc-4-05620
DOI See at publisher website ABS Show/hide abstract

There has been a persistent effort to improve efficacy of conventional antimycotic drugs. However, current antimycotic interventions have often limited efficiency in treating fungal pathogens, especially those resistant to drugs. Considering development of entirely new antimycotic drugs is a capital-intensive and time-consuming process, we investigated an alternative approach termed drug repurposing whereby new utility of various marketed, non-antifungal drugs could be repositioned as novel antimycotic agents. As a proof of concept, we applied chemosensitization as a new screening strategy, where combined application of a second compound, viz., chemosensitizer, with a conventional drug could enhance antifungal efficacy of the drug co-applied. Unlike the conventional combination therapy, a chemosensitizer itself does not necessarily have to possess an antifungal activity, but the chemosensitizer significantly debilitates defense systems of pathogens to drugs, enabling improved identification of antifungal activity of off-patent drugs. Of note, inclusion of fungal mutants, such as antioxidant mutants, could facilitate drug repurposing process by enhancing the sensitivity of antifungal screening. Altogether, our strategy could lead to high efficiency drug repurposing, which enhances the drug susceptibility of targeted fungal pathogens.